Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. T-Mobile (TMUS) downgraded to Hold from Buy at Deutsche Bank with analyst Matthew Niknam saying the risk/reward is more balanced at current levels amid intensifying competition in U.S. wireless. The analyst sees "limited incremental upside" from M&A scenarios and keeps a $68 price target for the shares. 2. Jazz Pharmaceuticals (JAZZ) downgraded to Neutral from Buy at Mizuho with analyst Irina Koffler saying the Xyrem generics will not reach the market ahead of prior expectations and lowered its price target to $150 from $162 saying the model fully credits other products and pipeline. 3. Ultragenyx (RARE) downgraded to Hold from Buy at Jefferies with analyst Brian Abrahams saying he sees potential headwinds as the company builds into small/less well-defined markets and believes the stock at current levels is fairly valued. 4. Bunge (BG) downgraded to Underweight from Neutral at JPMorgan with analyst Ann Duignan saying execution risks appear skewed to the downside in the near-term while "conditions conducive to a sale of sugar assets seem to have eroded in recent weeks." The analyst keeps a $70 price target for the shares. 5. 8point3 Energy (CAFD) was downgraded to Neutral from Buy at BofA/Merrill and Janney Capital, to Perform from Outperform at Oppenheimer, and to Market Perform from Outperform at Wells Fargo. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Raymond James raised the firm's price target on T-Mobile to $196 from $185 and keeps a Strong Buy rating on the shares. T-Mobile reported a slight beat and raise in Q1, plus made its first noticeable investment in fiber, the analyst tells investors in a research note. T-Mobile is one of the 20 stocks on the 2024 Raymond James Analyst Best Picks and is still 2+ years ahead in 5G deployment including the most mid-band spectrum that the firm thinks will continue to drive subscriber and service revenue growth.

TD Cowen lowered the firm's price target on T-Mobile to $202 from $204 and keeps a Buy rating on the shares. The firm said they posted good 1Q24 results with upside phone adds, upside EBITDA, solid churn, record low UG rates, and an EBITDA guide raise.

RBC Capital raised the firm's price target on T-Mobile to $188 from $184 and keeps an Outperform rating on the shares. The company posted mixed Q1 results, with service revenues in line, EBITDA and free cash flow above, and total revenue shy relative to consensus expectations, though the management also increased the guidance ranges for postpaid net additions, core adjusted EBITDA, and free cash flow, the analyst tells investors in a research note. T-Mobile will continue to outpace its peers in postpaid/phone subscriber growth, the firm added.

KeyBanc analyst Brandon Nispel raised the firm's price target on T-Mobile to $185 from $175 and keeps an Overweight rating on the shares. T-Mobile reported mixed results, with service revenue slightly below expectations and adjusted EBITDA higher on better expenses, the analyst tells investors in a research note. The firm thinks 2024 guidance should be achievable and likely has upside and maintains that T-Mobile has created a sustainable 5G network advantage and subscribers will follow, and expects to see high single digit EBITDA growth and double digit free cash flow growth, which should be returned to shareholders.

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

Bunge is down -6.6%, or -$7.20 to $102.42.